Eagle Pharmaceuticals Inc expected to post earnings of 91cents a share - Earnings Preview

Eagle Pharmaceuticals

04/11/2022 19:34

* Eagle Pharmaceuticals Inc  EGRX.OQ   EGRX.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
7. 
    * The Woodcliff Lake New Jersey-based  company is expected
to
report  a 55.8% increase in revenue to $62.077 million from
$39.85 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Eagle
Pharmaceuticals Inc
is for earnings of 91 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $43​, above​ its last closing price
of $31.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  3.32        3.36       1.56      Missed  -53.6
 Mar. 31 2022  3.88        3.88       4.04      Beat    4
 Dec. 31 2021  0.96        0.94       0.85      Missed  -9.6​
 Sep. 30 2021  0.83        0.83       0.56      Missed  -32.8
 ​​Jun.        0.75        0.80       0.93      Beat    16.3
 30 2021                                                
 Mar. 31 2021  0.74        0.65       0.24      Missed  -63.1​
 Dec. 31 2020  -0.20       -0.17      0.96      Beat    656.5
 Sep. 30 2020  0.33        0.30       1.17      Beat    296.6
 This summary was machine generated November 4 at 19:33 GMT.  All
figures in US dollars  unless otherwise stated